Scholarlink

<p>Lipid metabolism has emerged as a key factor in the pathophysiology of Parkinson’s disease (PD). While 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, has been implicated in neurodegenerative disorders, such as Alzheimer disease, its role in PD remains unexplored. Given the shared pathological features between these neurodegenerative disorders (such as lysosomal dysfunction and lipid dysregulation) we hypothesized that <i>HMGCR</i> genetic variability could influence PD susceptibility and/or phenotypic expression, particularly in early-onset cases (EOPD)<b>.</b> Therefore, we performed targeted sequencing of <i>HMGCR</i> in 1162 Spanish PD patients and analyzed associations with PD risk or age at onset. Replication was attempted in 436 PD cases from Parkinson’s Progression Markers Initiative (PPMI). We identified 21 <i>HMGCR</i> variants, including a likely pathogenic variant affecting the splice site of exon 4 (c.278-1G &gt; A) in a patient with early-onset PD (EOPD), rapid progression, and severe dyslipidemia. The rs5908 variant was significantly associated with EOPD in our cohort (OR = 2.22, p = 0.025). Further analysis revealed rs5908 is in linkage disequilibrium with rs115169875, an intronic variant with putative regulatory impact. Our findings nominate <i>HMGCR</i> as a candidate gene for PD development, particularly in early-onset cases. The metabolic profile of the c.278-1G &gt; A carrier parallels&#xa0;<i>GBA</i>-associated PD, suggesting convergent lipid-lysosomal pathways in neurodegeneration. While cohort differences highlight population-specific genetic effects, these findings underscore the importance of lipid pathways in PD and the need to explore&#xa0;<i>HMGCR</i>’s role in PD subtypes with metabolic comorbidity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HMGCR genetic variability in Parkinson’s disease in a Spanish cohort: associations with lipid metabolism and early onset

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月2日

查看全文
  • Rafael Díaz-Belloso,
  • Miguel Martín-Bornez,
  • Daniel Macías-García,
  • Sergio García-Díaz,
  • Marta Bonilla-Toribio,
  • Dolores Buiza-Rueda,
  • Rocío Pineda Sánchez,
  • Laura Muñoz-Delgado,
  • Elena Ojeda,
  • Silvia Jesús,
  • Astrid Adarmes-Gómez,
  • Fátima Carrillo,
  • Pablo Mir,
  • Pilar Gómez-Garre

摘要

Lipid metabolism has emerged as a key factor in the pathophysiology of Parkinson’s disease (PD). While 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, has been implicated in neurodegenerative disorders, such as Alzheimer disease, its role in PD remains unexplored. Given the shared pathological features between these neurodegenerative disorders (such as lysosomal dysfunction and lipid dysregulation) we hypothesized that HMGCR genetic variability could influence PD susceptibility and/or phenotypic expression, particularly in early-onset cases (EOPD). Therefore, we performed targeted sequencing of HMGCR in 1162 Spanish PD patients and analyzed associations with PD risk or age at onset. Replication was attempted in 436 PD cases from Parkinson’s Progression Markers Initiative (PPMI). We identified 21 HMGCR variants, including a likely pathogenic variant affecting the splice site of exon 4 (c.278-1G > A) in a patient with early-onset PD (EOPD), rapid progression, and severe dyslipidemia. The rs5908 variant was significantly associated with EOPD in our cohort (OR = 2.22, p = 0.025). Further analysis revealed rs5908 is in linkage disequilibrium with rs115169875, an intronic variant with putative regulatory impact. Our findings nominate HMGCR as a candidate gene for PD development, particularly in early-onset cases. The metabolic profile of the c.278-1G > A carrier parallels GBA-associated PD, suggesting convergent lipid-lysosomal pathways in neurodegeneration. While cohort differences highlight population-specific genetic effects, these findings underscore the importance of lipid pathways in PD and the need to explore HMGCR’s role in PD subtypes with metabolic comorbidity.